<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03290534</url>
  </required_header>
  <id_info>
    <org_study_id>CT006</org_study_id>
    <nct_id>NCT03290534</nct_id>
  </id_info>
  <brief_title>Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®</brief_title>
  <official_title>Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CivaTech Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CivaTech Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a feasibility study to determine the usefulness of a brachytherapy device that
      utilizes active components (palladium-103) of standard devices in a novel configuration,
      which may benefit lung cancer patients by reducing the radiation dose to critical structures,
      such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a
      surgical margin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Control Rate at 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>The local control rate in the region irradiated by CivaSheet.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from regional or distant recurrence</measure>
    <time_frame>1 year</time_frame>
    <description>Control rate for recurrences outside the local area irradiated by CivaSheet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>1 year</time_frame>
    <description>Time in months to any recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity graded on CTCAE 4.0 Scale</measure>
    <time_frame>1 year</time_frame>
    <description>pulmonary function, radiation pneumonitis, fatigue, lung fibrosis, etc.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Lung Cancer Stage I</condition>
  <condition>Lung Cancer Stage II</condition>
  <arm_group>
    <arm_group_label>CivaSheet Directional LDR Brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDA Cleared CivaSheet directional Pd-103 Brachytherapy Source is a planar radiation source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CivaSheet</intervention_name>
    <description>implanting CivaSheet for localized radiation dose delivery</description>
    <arm_group_label>CivaSheet Directional LDR Brachytherapy</arm_group_label>
    <other_name>brachytherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject signed inform consent

          -  Suspected or proven non-small cell lung cancer (NSCLC) in the upper lobes of the left
             or right lung

          -  Pre-operative criteria

          -  Lung nodule suspicious for NSCLC

          -  Mass ≤ 7 cm in maximum diameter by CT scan of the chest and upper abdomen

          -  Clinical stage I or Clinical stage II

          -  Not pregnant or nursing

          -  Negative pregnancy test in premenopausal women

          -  Fertile patients must use effective contraception

          -  More than 5 years since prior invasive malignancy unless non melanoma skin cancer or
             in-situ cancer

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abe Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MSKCC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carra Castagnero</last_name>
    <phone>9193145515</phone>
    <email>clinical@civatechoncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristy Perez, PhD</last_name>
    <phone>6789545744</phone>
    <email>kperez@civatechoncology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mission Hospital St Joesph</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathryn Irenze</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Spielsi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Lauro, BSN</last_name>
      <email>stephanie.lauro@nyulangone.org</email>
    </contact>
    <contact_backup>
      <last_name>Audrey Sorensen</last_name>
      <email>Audrey.Sorensen@nyulangone.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Zervos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Cooper, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 18, 2017</study_first_submitted>
  <study_first_submitted_qc>September 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2017</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wedge resection</keyword>
  <keyword>sublobar resection</keyword>
  <keyword>brachytherapy</keyword>
  <keyword>CivaSheet</keyword>
  <keyword>Pd-103</keyword>
  <keyword>CivaTech Oncology</keyword>
  <keyword>lung cancer</keyword>
  <keyword>lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

